MRVI Investors Have Opportunity to Lead Maravai Lifesciences Holdings, Inc. Securities Fraud Lawsuit

PRNewswireApr 20 13:10 ET

Express News | Maravai LifeSciences Q1 Revenue USD 56.6 Million Vs. IBES Estimate USD 44.1 Million

ReutersApr 17 15:48 ET

Maravai LifeSciences Holdings, Inc. Deadline Approaching: Kessler Topaz Meltzer & Check, LLP Reminds Maravai LifeSciences Holdings, Inc. Investors of Deadline in Securities Fraud Class Action Lawsuit

PRNewswireApr 15 19:46 ET

RBC Capital Maintains Maravai LifeSciences(MRVI.US) With Buy Rating, Maintains Target Price $7

Moomoo NewsApr 9 13:33 ET · Ratings

New Analyst Forecast: $MRVI Given $5.0 Price Target

Quiver QuantitativeMar 26 14:21 ET

Stifel Maintains Maravai LifeSciences(MRVI.US) With Buy Rating, Maintains Target Price $5

Moomoo NewsMar 26 13:31 ET · Ratings